Refarmed Chemicals presents Ciprofibrate, a crucial pharmaceutical material developed for clinical efficacy in managing lipid disorders. Developed with the utmost precision, Ciprofibrate is a fibrate-class drug specially formulated as a therapeutic agent to regulate high levels of cholesterol and triglycerides, factors leading to cardiovascular diseases. Our product is synthesized with rigorous compliance to quality standards, evidenced by its Good Manufacturing Practice (GMP) certification. The drug appears as a white or slightly yellow-white crystalline powder, indicative of its purity. Highly soluble in anhydrous ethanol and toluene yet practically insoluble in water, Ciprofibrate facilitates flexibility in pharmaceutical formulation, allowing for both tablet and capsule dosage forms in strengths of 100mg and 200mg. Targeting primary hypercholesterolemia (type IIa or IIb), mixed dyslipidemia, and as preventive treatment against cardiovascular events in high cholesterol patients, Ciprofibrate's composition facilitates the acceleration of cholesterol and triglyceride breakdown and removal from the body. Recommended for bi-daily intake alongside meals, the treatment's efficacy is augmented by adherence to healthy lifestyle choices, including a balanced diet and regular exercise. Safety parameters dictate careful administration especially to those with a history of gallbladder disease, and periodic liver function evaluations are advised. Contraindications include severe renal or hepatic conditions, pregnancy, breastfeeding, or known hypersensitivity to fibrates. Consultation with healthcare professionals is critical when concomitant medications are involved, particularly statins, anticoagulants, and antibiotics. Storage requirements for Ciprofibrate are straightforward — room temperature conditions away from light and moisture ensure stability. As a product from the storied catalogue of Refarmed Chemicals, now part of the DKSH Group, Ciprofibrate is accompanied by dependable documentation for Detailed and Master Files, affirming its reputable standard in pharmaceutical resources.
Products still subject to third-party patent protection might be available solely for R&D purposes.
